Cagrilintide: the amylin peptide paired with Retatrutide
Cagrilintide comes up more and more in conversations about weight management, especially since the CagriSema clinical trial program made the news. In the Peptivia catalog, its name appears as the partner of Retatrutide in a single vial. This article makes Cagrilintide itself the subject: what it is, how it works, and why researchers like to pair it.
What Cagrilintide is
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk and designed to be given once a week. Amylin itself is a peptide hormone released by the beta cells of the pancreas together with insulin every time you eat. This hormone signals fullness to the brain, slows gastric emptying, and holds back the glucagon spike after a meal.
Natural amylin breaks down quickly and clumps easily, so it is hard to use as it is. Cagrilintide is given a fatty acid chain so that it binds to albumin in the blood and lasts far longer. The same principle is used in semaglutide, which is why the two suit a once-weekly schedule.
How it works in the brainstem
Cagrilintide works on two receptors at once, the amylin receptor and the calcitonin receptor, so it is often called a dual amylin and calcitonin agonist. Its site of action is in the brainstem, mainly the area postrema and the dorsal vagal complex, regions that help regulate satiety and meal size.
Basic research published in the journal Nature Metabolism in June 2026 mapped more than 530 thousand cells in the brainstem and found two groups of nerve cells marked by the calcitonin receptor that respond to Cagrilintide. Mapping like this helps explain why the amylin pathway is seen as complementing the GLP-1 pathway, not merely repeating it.
On the same pathway there is another name that is more selective for the amylin receptor. The comparison is covered in Eloralintide and the amylin pathway.
Its clinical trial journey
- April 2021: a phase 1b trial in The Lancet studied Cagrilintide given together with semaglutide, including how the body processes the two.
- November 2021: a phase 2 trial in The Lancet tested several doses of once-weekly Cagrilintide at 57 research sites in ten countries.
- June 2025: the results of REDEFINE 1 and REDEFINE 2 were published in the New England Journal of Medicine. REDEFINE 1 involved 3,417 adults over 68 weeks and included a Cagrilintide-only group alongside the CagriSema combination.
- June 2026: three phase 3 REIMAGINE trials in people with type 2 diabetes were published in The Lancet and The Lancet Diabetes & Endocrinology.
Its clinical trial program is still ongoing and keeps adding to the picture of Cagrilintide over the long term.
Why Cagrilintide is often paired
The amylin pathway works through receptors different from those of incretin pathways such as GLP-1, so two satiety signals can be touched at the same time. In clinical trials, its partner is semaglutide, under the name CagriSema. In the Peptivia catalog, Cagrilintide is paired with Retatrutide, a peptide that works on three pathways: GLP-1, GIP, and glucagon.
One vial of Retatrutide + Cagrilintide contains 5 mg of Retatrutide and 5 mg of Cagrilintide. The reasons for combining the two are reviewed more fully in Retatrutide and Cagrilintide: why they are paired, while the practical questions before ordering are in the checklist for buying peptides online safely.
The full product details are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.
